CHC - Soft tissue repair
In the treatment of soft tissue injuries, often a supporting mesh or matrix is introduced to improve stability of the repair site.

Corline Biomedical supplies CHS heparin coatings to medical device makers and offers Renaparin for regenerative medicine.
corline.seCrawled Nov 11, 2026
In the treatment of soft tissue injuries, often a supporting mesh or matrix is introduced to improve stability of the repair site.
Corline Heparin Conjugate (CHC) is the core of Corline’s antithrombotic technology, used in Renaparin and CHS coatings for medical devices.
Patients with severe types of diabetes type 1 have difficulties controlling blood sugar levels, despite modern monitoring equipment and strict insulin regimes.
The Corline Heparin Surface (CHS) improves blood compatibility for medical devices in contact with blood, reducing clot risks and long-term effects.
Regenerative medicine advances rely on solutions that improve graft tolerance and patient safety by modifying immune responses.
Regenerative medicine aims to restore or establish clinical function in human or animal cells, tissues, or organs. Solutions improving graft tolerance enhance patient safety and treatment efficacy.
Q3 reported earnings for Corline Biomedical
Corline Biomedical AB (publ) invites shareholders to its annual general meeting on May 12, 2026.
The Centers for Medicare & Medicaid Services (CMS) updated reimbursement models for therapies in the United States.
Corline supplies its antithrombotic coating, the Corline Heparin Surface (CHS), to medical device customers using proprietary heparin technology. The company also offers Renaparin for regenerative medicine applications and provides reagent manufacturing and coating services in Uppsala, Sweden.
Corline Biomedical supplies antithrombotic and antiinflammatory surface coating solutions to customers in the medical device industry and to applications in the evolving field of regenerative medicine.
Corline Biomedical AB (publ) protects personal data and complies with the general data protection regulation.
Corline Biomedical expands early-stage growth as customer Kardium introduces the Globe catheter in the US, Canada, and additional markets. The company benefits from this partnership, which supports its medical device pipeline. The earnings report highlights progress in scaling operations amid rising demand for its cardiovascular solutions.
Corline Biomedical achieves the first commercial application of its CHS technology in a US-market product targeting cardiac arrhythmia. The company enters the **pacemaker-free atrial (PFA) treatment** space, expanding its clinical footprint beyond research. This marks a milestone in translating its proprietary platform into commercial cardiac therapies.
Corline Biomedical conducts a directed share issue to bolster its shareholder foundation. The move aims to solidify financial stability and support ongoing operations. Details on the terms or specific investors are not disclosed in the report.
Corline Biomedical raises **SEK 23 million** through a directed share issue to **Eiffel Investment Group** to accelerate customer acquisition in the **US medical technology market**. The funding supports expansion efforts in a key growth region for the company’s products.
Corline Biomedical’s Kardium unit secures FDA approval for its Globe system, enabling the launch of commercial operations. The approval follows regulatory validation of the device’s safety and efficacy. Redeye expresses optimism about the milestone, marking a transition to broader market availability.
Corline Biomedical presents strong 1-year study results for its Kardium CHS-coated Globe system. The data emphasizes safety outcomes, reinforcing the device’s potential in clinical applications. The study focuses on evaluating long-term performance and patient compatibility.